NetworkNewsBreaks – Tandem Diabetes Care (NASDAQ: TNDM) Shares Soar on FDA Approval, Commercial Launch of t:slim X2 with Dexcom G5 Mobile CGM Integration
Shares of Tandem Diabetes Care (NASDAQ: TNDM) are up 49% after the company this morning said it has received approval from the U.S. Food and Drug Administration (FDA) for its t:slim X2™ Insulin Pump with Dexcom G5® Mobile continuous glucose monitoring (CGM) integration. Additionally, the company announced the commercial launch of the product, which is the first sensor-augmented insulin pump approved to let users make treatment decisions without pricking their fingers. Approval of the t:slim X2 marks Tandem’s fifth new insulin pump launch in only five years. “The t:slim X2 Pump is designed to accelerate the pace in which we…







